Home » Stocks » BEAM

Beam Therapeutics Inc. (BEAM)

Stock Price: $66.14 USD -0.74 (-1.11%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $66.80 +0.66 (1.00%) May 13, 5:47 PM
Market Cap 4.06B
Revenue (ttm) 18,000
Net Income (ttm) -365.69M
Shares Out 62.58M
EPS (ttm) -6.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $66.14
Previous Close $66.88
Change ($) -0.74
Change (%) -1.11%
Day's Open 67.90
Day's Range 64.00 - 72.10
Day's Volume 981,102
52-Week Range 18.76 - 126.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Beam Therapeutics Inc (NASDAQ: BEAM) reported a wider Q1 net loss of $201.6 million compared to $31.7 million a year ago, on higher R&D costs of $190.1 million, up from $21.5 million in Q1 2020. It incl...

2 days ago - Benzinga

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -365.28% and -99.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

Data from Beam's Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52%

2 days ago - GlobeNewsWire

It definitely made investors a lot of money over the last decade. And its future could be brighter than the past.

Other stocks mentioned: EXAS, MRNA, NTLA, REGN, XBI
6 days ago - The Motley Fool

Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Gene therapies could be poised to enter an era of extraordinarily rapid advancement.

Other stocks mentioned: INTC, NTLA
1 week ago - The Motley Fool

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...

2 weeks ago - GlobeNewsWire

Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Company's Pioneering Work in Developing Base Editors

3 weeks ago - GlobeNewsWire

Here's why she likes them so much.

Other stocks mentioned: FATE, TXG
3 weeks ago - The Motley Fool

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Other stocks mentioned: CLLS, CRSP, EDIT, NTLA
1 month ago - InvestorPlace

Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that drug...

1 month ago - GlobeNewsWire

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...

Other stocks mentioned: BLUE, CRSP, EDIT, NTLA
2 months ago - InvestorPlace

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...

2 months ago - GlobeNewsWire

Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx s...

2 months ago - Benzinga

Beam Therapeutics announced it had acquired Guide Therapeutics, a maker of components for genetic medicines — and Beam stock tumbled. Broadly, biotech stocks were under pressure.

2 months ago - Investors Business Daily

GuideTx's Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing GuideTx's Proprietary LNP Screening Technology and Li...

2 months ago - GlobeNewsWire

Beam Therapeutics (BEAM) is pioneering a new evolution of gene editing techniques that could be the key to making safer genomic medicines. The post This Unique Gene Editing Stock Could Turn into the Gen...

3 months ago - InvestorPlace

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, investors mig...

Other stocks mentioned: CRSP, EDIT, NTLA, SWTX
3 months ago - GuruFocus

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today anno...

3 months ago - GlobeNewsWire

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on In...

Other stocks mentioned: CLLS, CLXT, CRSP, EDIT, NTLA, SGMO
3 months ago - InvestorPlace

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kate ...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Beam Therapeutics (BEAM) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John ...

4 months ago - GlobeNewsWire

Listen in to hear how you can profit in 2021 and beyond

Other stocks mentioned: ARKG, BEEM, CRSP, EH, F, GIX, LAZR ...
5 months ago - InvestorPlace

If analysts are even close to being on target, it may be time for early investors to cash in on their shares of Beam Therapeutics Inc. (NASDAQ:BEAM). The stock of the Cambridge, Massachusetts-based biot...

5 months ago - GuruFocus

Beam Therapeutics was co-founded by David Liu, who invented base editing and prime editing technologies for gene editing. David Liu also co-founded Editas.

5 months ago - Seeking Alpha

BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed ; Will Support Planned IND Submi ssion in the Second Half of 2021

5 months ago - GlobeNewsWire

Magazine honors company for second year in a row Magazine honors company for second year in a row

5 months ago - GlobeNewsWire

Novel Base Edit ors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation C orrection than Required to Restore Glucose H omeostasis

6 months ago - GlobeNewsWire

BEAM -201 , a n Off the Shelf Allogeneic CD7-Targeting CAR-T , Named as Development Candidate for Treatment of T-ALL ; First Cell Therapy Featuring Four Simultaneous Genetic Edits ; Demonstrates 96-99% ...

6 months ago - GlobeNewsWire

BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Ca ndidate for Treatment of T- Cell Acute Lymphoblastic Leukemia

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John ...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the prici...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the comm...

7 months ago - GlobeNewsWire

A rumored merger has investors excited, although details are scarce.

Other stocks mentioned: EDIT
9 months ago - The Motley Fool

Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher on Wednesday after William Blair initiated coverage on the company's stock with an Outperform rating and announced a $33 price target.

9 months ago - Benzinga

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector® Platform for Next Generation CAR-T Therapeutics

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that m...

9 months ago - GlobeNewsWire

Shares of a Cambridge, Massachusetts-based biotechnology company that is taking a different approach to gene editing have gained more than 25% since its early February initial public offering.

11 months ago - GuruFocus

Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo

1 year ago - GlobeNewsWire

Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs Successful Initial Public Offering Completed and Continued Advancement of Broad P...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key l...

1 year ago - GlobeNewsWire

Beam Therapeutics Inc. (NASDAQ: BEAM) is not exactly a household name in corporate America.

1 year ago - 24/7 Wall Street

Beam Therapeutics' new approach offers more precision than CRISPR.

1 year ago - The Motley Fool

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies... [Read more...]

Industry
Biotechnology
IPO Date
Feb 6, 2020
Stock Exchange
NASDAQ
Ticker Symbol
BEAM
Full Company Profile

Financial Performance

In 2020, BEAM's revenue was $24,000, an increase of 33.33% compared to the previous year's $18,000. Losses were -$194.59 million, 148.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is 94.57, which is an increase of 42.98% from the latest price.

Price Target
$94.57
(42.98% upside)
Analyst Consensus: Buy